Analyze Diet
Equine veterinary journal2022; 55(2); 325-335; doi: 10.1111/evj.13582

Conditioned serum in vitro treatment of chondrocyte pellets and osteoarthritic explants.

Abstract: Autologous conditioned serum (ACS) is used to treat osteoarthritis in horses, although its effects are not fully investigated. Objective: To investigate the effects of equine serum and conditioned serum on chondrocytes stimulated with interleukin (IL)-1β and cartilage explants with mild osteoarthritis. Methods: In vitro experimental study. Methods: The effect of three different serum preparations (unincubated control [PS], serum incubated 24 h [PS24h] and serum incubated 24 h in ACS containers [PCS]) pooled from lame horses were tested in two in vitro models. IL-1β and IL-1 receptor antagonist (IL-1Ra) concentrations were measured in all sera. In model 1, chondrocyte pellet cultures were stimulated with IL-1β prior to treatment with the serum preparations for 2 and 48 h. Microarray, polymerase chain reaction, and matrix metallopeptidase-13 analyses were performed. In model 2, cartilage explants from horses with structural osteoarthritis were treated with PS or PCS on days 0, 6 and 12, or left untreated, and evaluated at day 24 using the OARSI grading scale for histological evaluation of articular cartilage. Results: The IL-1Ra concentration in PS24h and PCS was significantly higher than in PS. In model 1, inflammation- and cartilage matrix degradation-related genes were upregulated after 48 h in all treatment groups versus untreated controls. Cartilage matrix molecules, aggrecan and collagens, were downregulated in PS24h- and PCS-treated pellets versus untreated controls. Growth factor signalling genes were upregulated-FGF7 in all treatment groups, BMP2 in PS24h-, and INHBA in PCS-treated-compared with untreated controls. In model 2, the OARSI score at day 24 was not significantly different between treatment groups. Conclusions: Results from in vitro models cannot be directly translated to in vivo situations. Conclusions: In vitro treatment with conditioned serum did not alleviate IL-1β-induced responses in chondrocyte pellets or lead to morphological improvement in osteoarthritic cartilage explants. Unassigned: Suero autólogo acondicionado (ACS) es usado para tartar osteoartritis en caballos, aunque sus efectos no han sido completamente investigados. Objective: Investigar los efectos de suero equino y suero acondicionado en condrocitos estimulados con interleukina (IL)-1β y explantes de cartílago con osteoartritis leve. DISEÑO DEL ESTUDIO: Estudio experimental in vitro. MÉTODOS: El efecto de tres preparaciones séricas diferentes (control no incubado (PS), suero incubado 24 h (PS24h), y suero incubado 24 h en frascos ACS (PCS)) combinados y obtenidos de caballos cojos fueron probados en dos modelos in vitro. Las concentraciones de IL-1β y de receptor antagonista de IL-1 (IL-1Ra) fueron medidas en todos los sueros. En el modelo 1, los cultivos de pellets de condrocitos fueron estimulados con IL-1β antes de ser tratados con las preparaciones séricas durante 2 y 48 h. Se realizaron análisis de micromatrices, reacciones de polimerasa en cadena y de matriz de metalopeptidasa-13. En el modelo 2, explantaciones de cartílago proveniente de caballos con osteoartritis estructural fueron tratados con PS o PCS en los días 0, 6 y 12, o dejados sin tartar, y evaluados al día 24 usando la escala de graduación OARSI para evaluación histológica de cartílago articular. Results: La concentración de IL-1Ra en PS24h y PCS fue significativamente mayor que en PS. En el modelo 1, los genes relacionados a la inflamación y a la degradación de la matriz cartilaginosa estaban aumentados después de 48 h en todos los grupos tratados en comparación a los controles no tratados. Las moléculas de matriz cartilaginosa, agrecanos y colágenos estaban disminuidos en los pellets PS24h y PCS versus los controles no tratados. Los genes de señales de factores de crecimiento FGF7 estaban aumentados en todos los grupos tratados, BMP2 en PS24h y INHBA in PCS en comparación con los controles no tratados. En el modelo 2, la escala OARSI al día 24 no fue significativamente distinta entre los grupos de tratamientos. Unassigned: Los resultados de modelos in vitro no pueden ser directamente aplicados a situaciones in vivo. Conclusions: El tratamiento in vitro con suero acondicionado no alivió las respuestas inducidas por IL-1β en pellets de condrocitos o llevo a mejoramiento morfológico en explantes de cartílago con osteoartritis.
Publication Date: 2022-06-06 PubMed ID: 35514185PubMed Central: PMC10084271DOI: 10.1111/evj.13582Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
  • Journal Article

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

This research investigates the treatment effects of autologous conditioned serum (ACS), specifically incubated horse serum, on osteoarthritic chondrocytes and cartilage explants. The in vitro study revealed no notable improvements in the inflammation response or the structure of osteoarthritic tissue after ACS treatment.

Research Objective and Methods

  • The study’s aim was to understand the impact of equine serum and conditioned serum on chondrocytes (cells in the cartilage) that have been stimulated with interleukin (IL)-1β, a pro-inflammatory cytokine, and cartilage explants (fragments) displaying mild osteoarthritis.
  • This was an in vitro experimental study that made use of three different types of serum preparations. The serums were pooled from lame horses. The serum types included unincubated control (PS), serum incubated for 24 hours (PS24h), and serum incubated for the same period in ACS containers (PCS).
  • The concentrations of IL-1β and IL-1 receptor antagonist (IL-1Ra) were measured in all serums. This was done to check for necessary proteins for counteracting inflammatory responses.
  • Experimental Models and Analysis

    • The first experimental model involved treating chondrocyte pellet cultures with IL-1β to stimulate an inflammatory response before subjecting them to the serum treatments. After specified periods, reactions including microarray (gene activity tests), polymerase chain reaction (DNA tests), and matrix metalloproteinase-13 (a protein-degrading enzyme) were monitored.
    • In the second model, cartilage explants taken from horses showing signs of osteoarthritis were treated with PS or PCS serum at specific intervals or left untreated. The severity of osteoarthritis and the effects of the treatment were evaluated using the OARSI grading scale for histological evaluation of articular cartilage.
    • Results and Conclusion

      • In both trial models, IL-1Ra concentration was significantly higher in PS24h and PCS compared to PS.
      • In the chondrocyte pellet cultures (Model 1), genes related to inflammation and cartilage matrix degradation were elevated after 48 hours in all treatment groups, compared to the untreated controls. Cartilage matrix molecules, like aggrecan and collagen, were less abundant in the treatments with PS24h and PCS compared to untreated controls.
      • In the cartilage explant trial (Model 2), the OARSI score at day 24 showed no significant differences between the treatment groups, suggesting no notable improvement in osteoarthritis severity.
      • The study concluded that the in vitro treatment with conditioned serum did not alleviate IL-1β-induced responses in the chondrocyte pellets or lead to any morphological improvement in the osteoarthritic cartilage explants.

Cite This Article

APA
Löfgren M, Ekman S, Ekholm J, Engström M, Fjordbakk CT, Svala E, Holm Forsström K, Lindahl A, Skiöldebrand E. (2022). Conditioned serum in vitro treatment of chondrocyte pellets and osteoarthritic explants. Equine Vet J, 55(2), 325-335. https://doi.org/10.1111/evj.13582

Publication

ISSN: 2042-3306
NlmUniqueID: 0173320
Country: United States
Language: English
Volume: 55
Issue: 2
Pages: 325-335

Researcher Affiliations

Löfgren, Maria
  • Department of Biomedical Sciences and Veterinary Public Health, Swedish University of Agricultural Sciences, Uppsala, Sweden.
Ekman, Stina
  • Department of Biomedical Sciences and Veterinary Public Health, Swedish University of Agricultural Sciences, Uppsala, Sweden.
Ekholm, Josefine
  • Department of Clinical Chemistry and Transfusion Medicine, Institute of Biomedicine, Sahlgrenska University Hospital, Gothenburg University, Gothenburg, Sweden.
Engström, Mona
  • Department of Clinical Chemistry and Transfusion Medicine, Institute of Biomedicine, Sahlgrenska University Hospital, Gothenburg University, Gothenburg, Sweden.
Fjordbakk, Cathrine T
  • Faculty of Veterinary Medicine, Department of Companion Animal Clinical Sciences, Norwegian University of Life Sciences, Oslo, Norway.
Svala, Emilia
  • Department of Biomedical Sciences and Veterinary Public Health, Swedish University of Agricultural Sciences, Uppsala, Sweden.
  • Department of Clinical Chemistry and Transfusion Medicine, Institute of Biomedicine, Sahlgrenska University Hospital, Gothenburg University, Gothenburg, Sweden.
Holm Forsström, Karin
  • Equine Clinic, University Animal Hospital, Swedish University of Agricultural Sciences, Uppsala, Sweden.
Lindahl, Anders
  • Department of Clinical Chemistry and Transfusion Medicine, Institute of Biomedicine, Sahlgrenska University Hospital, Gothenburg University, Gothenburg, Sweden.
Skiöldebrand, Eva
  • Department of Biomedical Sciences and Veterinary Public Health, Swedish University of Agricultural Sciences, Uppsala, Sweden.
  • Department of Clinical Chemistry and Transfusion Medicine, Institute of Biomedicine, Sahlgrenska University Hospital, Gothenburg University, Gothenburg, Sweden.

MeSH Terms

  • Horses
  • Animals
  • Chondrocytes / metabolism
  • Interleukin 1 Receptor Antagonist Protein / metabolism
  • Interleukin 1 Receptor Antagonist Protein / pharmacology
  • Osteoarthritis / therapy
  • Osteoarthritis / veterinary
  • Cartilage, Articular
  • Inflammation / metabolism
  • Inflammation / veterinary
  • Cells, Cultured
  • Horse Diseases / metabolism

Grant Funding

  • Valborg Jacobssons Fond
  • Svelands Stiftelse
  • H-16-47-182 / Swedish-Norwegian Foundation for Equine Research

Conflict of Interest Statement

The authors declare no conflict of interest.

References

This article includes 53 references
  1. Kidd JA, Fuller C, Barr RS. Osteoarthritis in the horse. Equine Vet Educ 2001;13:160–8.
  2. Frisbie DD, Ghivizzani SC, Robbins PD, Evans CH, McIlwraith CW. Treatment of experimental equine osteoarthritis by in vivo delivery of the equine interleukin-1 receptor antagonist gene.. Gene Ther 2002 Jan;9(1):12-20.
    pubmed: 11850718doi: 10.1038/sj.gt.3301608google scholar: lookup
  3. Meijer H, Reinecke J, Becker C, Tholen G, Wehling P. The production of anti-inflammatory cytokines in whole blood by physico-chemical induction.. Inflamm Res 2003 Oct;52(10):404-7.
    pubmed: 14520515doi: 10.1007/s00011-003-1197-1google scholar: lookup
  4. Hraha TH, Doremus KM, McIlwraith CW, Frisbie DD. Autologous conditioned serum: the comparative cytokine profiles of two commercial methods (IRAP and IRAP II) using equine blood.. Equine Vet J 2011 Sep;43(5):516-21.
  5. Frisbie DD, Kawcak CE, Werpy NM, Park RD, McIlwraith CW. Clinical, biochemical, and histologic effects of intra-articular administration of autologous conditioned serum in horses with experimentally induced osteoarthritis.. Am J Vet Res 2007 Mar;68(3):290-6.
    pubmed: 17331019doi: 10.2460/ajvr.68.3.290google scholar: lookup
  6. Wehling P, Moser C, Frisbie D, McIlwraith CW, Kawcak CE, Krauspe R, Reinecke JA. Autologous conditioned serum in the treatment of orthopedic diseases: the orthokine therapy.. BioDrugs 2007;21(5):323-32.
  7. Fjordbakk CT, Johansen GM, Løvås AC, Oppegård KL, Storset AK. Surgical stress influences cytokine content in autologous conditioned serum.. Equine Vet J 2015 Mar;47(2):212-7.
    pubmed: 24735323doi: 10.1111/evj.12277google scholar: lookup
  8. Rutgers M, Saris DB, Dhert WJ, Creemers LB. Cytokine profile of autologous conditioned serum for treatment of osteoarthritis, in vitro effects on cartilage metabolism and intra-articular levels after injection.. Arthritis Res Ther 2010;12(3):R114.
    pmc: PMC2911907pubmed: 20537160doi: 10.1186/ar3050google scholar: lookup
  9. Marques-Smith P, Kallerud AS, Johansen GM, Boysen P, Jacobsen AM, Reitan KM, Henriksen MM, Löfgren M, Fjordbakk CT. Is clinical effect of autologous conditioned serum in spontaneously occurring equine articular lameness related to ACS cytokine profile?. BMC Vet Res 2020 Jun 8;16(1):181.
    pmc: PMC7278142pubmed: 32513154doi: 10.1186/s12917-020-02391-7google scholar: lookup
  10. Ley CJ, Ekman S, Dahlberg LE, Björnsdóttir S, Hansson K. Evaluation of osteochondral sample collection guided by computed tomography and magnetic resonance imaging for early detection of osteoarthritis in centrodistal joints of young Icelandic horses.. Am J Vet Res 2013 Jun;74(6):874-87.
    pubmed: 23718656doi: 10.2460/ajvr.74.6.874google scholar: lookup
  11. Ley C, Svala E, Nilton A, Lindahl A, Eloranta ML, Ekman S, Skiöldebrand E. Effects of high mobility group box protein-1, interleukin-1β, and interleukin-6 on cartilage matrix metabolism in three-dimensional equine chondrocyte cultures.. Connect Tissue Res 2011;52(4):290-300.
    pubmed: 21117899doi: 10.3109/03008207.2010.523803google scholar: lookup
  12. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.. Methods 2001 Dec;25(4):402-8.
    pubmed: 11846609doi: 10.1006/meth.2001.1262google scholar: lookup
  13. McIlwraith CW, Frisbie DD, Kawcak CE, Fuller CJ, Hurtig M, Cruz A. The OARSI histopathology initiative - recommendations for histological assessments of osteoarthritis in the horse.. Osteoarthritis Cartilage 2010 Oct;18 Suppl 3:S93-105.
    pubmed: 20864027doi: 10.1016/j.joca.2010.05.031google scholar: lookup
  14. Olsson U. Statistics for Life Science 1. Lund, Studentlitteratur; 2011.
  15. Littell R, Milliken G, Stroup W, Wolfinger R, Schabenberger O. SAS for mixed models. 2nd ed. Cary, NC: SAS Institute Inc.; 2006.
  16. Li C, Wong WH. Model-based analysis of oligonucleotide arrays: expression index computation and outlier detection.. Proc Natl Acad Sci U S A 2001 Jan 2;98(1):31-6.
    pmc: PMC14539pubmed: 11134512doi: 10.1073/pnas.98.1.31google scholar: lookup
  17. Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, Scherf U, Speed TP. Exploration, normalization, and summaries of high density oligonucleotide array probe level data.. Biostatistics 2003 Apr;4(2):249-64.
    pubmed: 12925520doi: 10.1093/biostatistics/4.2.249google scholar: lookup
  18. Smyth GK. Linear models and empirical bayes methods for assessing differential expression in microarray experiments.. Stat Appl Genet Mol Biol 2004;3:Article3.
    doi: 10.2202/1544-6115.1027pubmed: 16646809google scholar: lookup
  19. Smyth GK. Limma: linear models for microarray data. In: Gentleman R, Carey VJ, Huber W, Irizarry RA, Dudoit S, editors. Bioinformatics and computational biology solutions using R and Bioconductor. New York: Springer; 2005. p. 397–420.
  20. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Series B Methodol 1995;57:289–300.
  21. Wojdasiewicz P, Poniatowski ŁA, Szukiewicz D. The role of inflammatory and anti-inflammatory cytokines in the pathogenesis of osteoarthritis.. Mediators Inflamm 2014;2014:561459.
    pmc: PMC4021678pubmed: 24876674doi: 10.1155/2014/561459google scholar: lookup
  22. Rowan AD, Koshy PJ, Shingleton WD, Degnan BA, Heath JK, Vernallis AB, Spaull JR, Life PF, Hudson K, Cawston TE. Synergistic effects of glycoprotein 130 binding cytokines in combination with interleukin-1 on cartilage collagen breakdown.. Arthritis Rheum 2001 Jul;44(7):1620-32.
  23. Hui W, Bell M, Carroll G. Oncostatin M (OSM) stimulates resorption and inhibits synthesis of proteoglycan in porcine articular cartilage explants.. Cytokine 1996 Jun;8(6):495-500.
    pubmed: 8818547doi: 10.1006/cyto.1996.0067google scholar: lookup
  24. Wiegertjes R, van de Loo FAJ, Blaney Davidson EN. A roadmap to target interleukin-6 in osteoarthritis.. Rheumatology (Oxford) 2020 Oct 1;59(10):2681-2694.
  25. van de Loo FA, Kuiper S, van Enckevort FH, Arntz OJ, van den Berg WB. Interleukin-6 reduces cartilage destruction during experimental arthritis. A study in interleukin-6-deficient mice.. Am J Pathol 1997 Jul;151(1):177-91.
    pmc: PMC1857913pubmed: 9212744
  26. Maier R, Ganu V, Lotz M. Interleukin-11, an inducible cytokine in human articular chondrocytes and synoviocytes, stimulates the production of the tissue inhibitor of metalloproteinases.. J Biol Chem 1993 Oct 15;268(29):21527-32.
    pubmed: 8408003
  27. Svala E, Thorfve AI, Ley C, Henriksson HK, Synnergren JM, Lindahl AH, Ekman S, Skiöldebrand ES. Effects of interleukin-6 and interleukin-1β on expression of growth differentiation factor-5 and Wnt signaling pathway genes in equine chondrocytes.. Am J Vet Res 2014 Feb;75(2):132-40.
    pubmed: 24471749doi: 10.2460/ajvr.75.2.132google scholar: lookup
  28. Löfgren M, Svala E, Lindahl A, Skiöldebrand E, Ekman S. Time-dependent changes in gene expression induced in vitro by interleukin-1β in equine articular cartilage.. Res Vet Sci 2018 Jun;118:466-476.
    pubmed: 29747133doi: 10.1016/j.rvsc.2018.04.013google scholar: lookup
  29. Watts MR, Hegedus OC, Eades SC, Belknap JK, Burns TA. Association of sustained supraphysiologic hyperinsulinemia and inflammatory signaling within the digital lamellae in light-breed horses.. J Vet Intern Med 2019 May;33(3):1483-1492.
    pmc: PMC6524466pubmed: 30912229doi: 10.1111/jvim.15480google scholar: lookup
  30. Li ZM, Li M. Improvement in orthopedic outcome score and reduction in IL-1β, CXCL13, and TNF-α in synovial fluid of osteoarthritis patients following arthroscopic knee surgery.. Genet Mol Res 2017 Jul 6;16(3).
    doi: 10.4238/gmr16039487pubmed: 28692119google scholar: lookup
  31. Ye G, Peng C, Gao Z, Xiao J, Mei L. Effects of arthroscopic knee surgery on IL‐1β, CXCL13 and TNF‐α in the knee joint fluid of knee osteoarthritis patients and their correlation with clinical outcomes. Int J Clin Exp Pathol 2017;10:1690–6.
  32. Peters VA, Joesting JJ, Freund GG. IL-1 receptor 2 (IL-1R2) and its role in immune regulation.. Brain Behav Immun 2013 Aug;32:1-8.
    pmc: PMC3610842pubmed: 23195532doi: 10.1016/j.bbi.2012.11.006google scholar: lookup
  33. Goldring MB, Goldring SR. Osteoarthritis.. J Cell Physiol 2007 Dec;213(3):626-34.
    pubmed: 17786965doi: 10.1002/jcp.21258google scholar: lookup
  34. Brew K, Nagase H. The tissue inhibitors of metalloproteinases (TIMPs): an ancient family with structural and functional diversity.. Biochim Biophys Acta 2010 Jan;1803(1):55-71.
  35. Abo T, Nagayasu T, Hishikawa Y, Tagawa T, Nanashima A, Yamayoshi T, Matsumoto K, An S, Koji T. Expression of keratinocyte growth factor and its receptor in rat tracheal cartilage: possible involvement in wound healing of the damaged cartilage.. Acta Histochem Cytochem 2010 Jun 28;43(3):89-98.
    pmc: PMC2896696pubmed: 20628626doi: 10.1267/ahc.10006google scholar: lookup
  36. Cunningham NS, Jenkins NA, Gilbert DJ, Copeland NG, Reddi AH, Lee SJ. Growth/differentiation factor-10: a new member of the transforming growth factor-beta superfamily related to bone morphogenetic protein-3.. Growth Factors 1995;12(2):99-109.
    pubmed: 8679252doi: 10.3109/08977199509028956google scholar: lookup
  37. Hopwood B, Tsykin A, Findlay DM, Fazzalari NL. Microarray gene expression profiling of osteoarthritic bone suggests altered bone remodelling, WNT and transforming growth factor-beta/bone morphogenic protein signalling.. Arthritis Res Ther 2007;9(5):R100.
    doi: 10.1186/ar2301pmc: PMC2212557pubmed: 17900349google scholar: lookup
  38. Finnson KW, Chi Y, Bou-Gharios G, Leask A, Philip A. TGF-b signaling in cartilage homeostasis and osteoarthritis.. Front Biosci (Schol Ed) 2012 Jan 1;4:251-68.
    pubmed: 22202058doi: 10.2741/s266google scholar: lookup
  39. Blaney Davidson EN, van der Kraan PM, van den Berg WB. TGF-beta and osteoarthritis.. Osteoarthritis Cartilage 2007 Jun;15(6):597-604.
    pubmed: 17391995doi: 10.1016/j.joca.2007.02.005google scholar: lookup
  40. Blaney Davidson EN, Vitters EL, van Lent PL, van de Loo FA, van den Berg WB, van der Kraan PM. Elevated extracellular matrix production and degradation upon bone morphogenetic protein-2 (BMP-2) stimulation point toward a role for BMP-2 in cartilage repair and remodeling.. Arthritis Res Ther 2007;9(5):R102.
    pmc: PMC2212581pubmed: 17922907doi: 10.1186/ar2305google scholar: lookup
  41. Legendre F, Ollitrault D, Gomez-Leduc T, Bouyoucef M, Hervieu M, Gruchy N, Mallein-Gerin F, Leclercq S, Demoor M, Galéra P. Enhanced chondrogenesis of bone marrow-derived stem cells by using a combinatory cell therapy strategy with BMP-2/TGF-β1, hypoxia, and COL1A1/HtrA1 siRNAs.. Sci Rep 2017 Jun 13;7(1):3406.
    pmc: PMC5469741pubmed: 28611369doi: 10.1038/s41598-017-03579-ygoogle scholar: lookup
  42. Zhai G, Doré J, Rahman P. TGF-β signal transduction pathways and osteoarthritis.. Rheumatol Int 2015 Aug;35(8):1283-92.
    pubmed: 25773660doi: 10.1007/s00296-015-3251-zgoogle scholar: lookup
  43. Uutela M, Wirzenius M, Paavonen K, Rajantie I, He Y, Karpanen T, Lohela M, Wiig H, Salven P, Pajusola K, Eriksson U, Alitalo K. PDGF-D induces macrophage recruitment, increased interstitial pressure, and blood vessel maturation during angiogenesis.. Blood 2004 Nov 15;104(10):3198-204.
    pubmed: 15271796doi: 10.1182/blood-2004-04-1485google scholar: lookup
  44. Pohlers D, Huber R, Ukena B, Kinne RW. Expression of platelet-derived growth factors C and D in the synovial membrane of patients with rheumatoid arthritis and osteoarthritis.. Arthritis Rheum 2006 Mar;54(3):788-94.
    pubmed: 16508943doi: 10.1002/art.21670google scholar: lookup
  45. Lasarzik de Ascurra J, Ehrle A, Einspanier R, Lischer C. Influence of Incubation Time and Incubation Tube on the Cytokine and Growth Factor Concentrations of Autologous Conditioned Serum in Horses.. J Equine Vet Sci 2019 Apr;75:30-34.
    pubmed: 31002089doi: 10.1016/j.jevs.2018.12.015google scholar: lookup
  46. Linardi RL, Dodson ME, Moss KL, King WJ, Ortved KF. The Effect of Autologous Protein Solution on the Inflammatory Cascade in Stimulated Equine Chondrocytes.. Front Vet Sci 2019;6:64.
    pmc: PMC6414419pubmed: 30895181doi: 10.3389/fvets.2019.00064google scholar: lookup
  47. Sawyere DM, Lanz OI, Dahlgren LA, Barry SL, Nichols AC, Werre SR. Cytokine and Growth Factor Concentrations in Canine Autologous Conditioned Serum.. Vet Surg 2016 Jul;45(5):582-6.
    pubmed: 27357270doi: 10.1111/vsu.12506google scholar: lookup
  48. Magalon J, Bausset O, Veran J, Giraudo L, Serratrice N, Magalon G, Dignat-George F, Sabatier F. Physico-chemical factors influencing autologous conditioned serum purification.. Biores Open Access 2014 Feb 1;3(1):35-8.
    pmc: PMC3929001pubmed: 24570844doi: 10.1089/biores.2013.0041google scholar: lookup
  49. Lasarzik J, Bondzio A, Rettig M, Estrada R, Klaus C, Ehrle A. Evaluation of two protocols using autologous conditioned serum for intra‐articular therapy of equine osteoarthritis: a pilot study monitoring cytokines and cartilage‐specific biomarkers. J Equine Vet Sci 2018;60:35–42.
  50. Velloso Alvarez A, Boone LH, Pondugula SR, Caldwell F, Wooldridge AA. Effects of Autologous Conditioned Serum, Autologous Protein Solution, and Triamcinolone on Inflammatory and Catabolic Gene Expression in Equine Cartilage and Synovial Explants Treated With IL-1β in Co-culture.. Front Vet Sci 2020;7:323.
    pmc: PMC7332692pubmed: 32671108doi: 10.3389/fvets.2020.00323google scholar: lookup
  51. Carlson ER, Stewart AA, Carlson KL, Durgam SS, Pondenis HC. Effects of serum and autologous conditioned serum on equine articular chondrocytes treated with interleukin-1β.. Am J Vet Res 2013 May;74(5):700-5.
    pubmed: 23627382doi: 10.2460/ajvr.74.5.700google scholar: lookup
  52. Johnson CI, Argyle DJ, Clements DN. In vitro models for the study of osteoarthritis.. Vet J 2016 Mar;209:40-9.
    pubmed: 26831151doi: 10.1016/j.tvjl.2015.07.011google scholar: lookup
  53. Ehrle A, Lischer CJ, Lasarzik J, Einspanier R, Bondzio A. Synovial fluid and serum concentrations of interleukin‐1 receptor antagonist and interleukin‐1ß in naturally occurring equine osteoarthritis and septic arthritis. J Equine Vet Sci 2015;35(10):815–22.

Citations

This article has been cited 4 times.
  1. Yuan C, Ang SP, Hasoon JJ, Tolba R, Ruan QZ, Lam CM, Lo Bianco G, Christo PJ, Robinson CL. Dual-Action Regenerative Therapies: Regeneration and Antimicrobial Effects of Platelet- and Marrow-Derived Biologics. Biomedicines 2025 Nov 20;13(11).
    doi: 10.3390/biomedicines13112832pubmed: 41301922google scholar: lookup
  2. Roth SP, Liso G, Brehm W, Wagner B, Schnabel CL, Troillet A. Selected cytokine and chemokine concentrations in equine autologous conditioned serum are similar under defined and practically relevant storage conditions. Front Vet Sci 2025;12:1588240.
    doi: 10.3389/fvets.2025.1588240pubmed: 40496923google scholar: lookup
  3. Della Tommasa S, Brehm W, Farì G, Bernetti A, Imperante A. Use of Autologous Conditioned Serum (ACS) for Osteoarthritis Treatment in Horses: A Systematic Review of Clinical Data. Vet Sci 2023 Dec 18;10(12).
    doi: 10.3390/vetsci10120707pubmed: 38133258google scholar: lookup
  4. Fan M, Zhang J, Zhou L, Chen Z, Bao R, Zheng L, Tong P, Ma Y, Shan L. Intra-articular injection of placental mesenchymal stromal cells ameliorates pain and cartilage anabolism/catabolism in knee osteoarthritis. Front Pharmacol 2022;13:983850.
    doi: 10.3389/fphar.2022.983850pubmed: 36523496google scholar: lookup